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Abstract
!
Type 2 diabetes mellitus is a metabolic disease
characterized by persistent hyperglycemia. High
blood sugar can produce long-term complications
such as cardiovascular and renal disorders, reti-
nopathy, and poor blood flow. Its development
can be prevented or delayed in people with im-
paired glucose tolerance by implementing life-
style changes or the use of therapeutic agents.
Some of these drugs have been obtained from
plants or have a microbial origin, such as galegine
isolated from Galega officinalis, which has a great
similarity to the antidiabetic drug metformin.
Picnogenol, acarbose, miglitol, and voglibose are
other antidiabetic products of natural origin. This
review compiles the principal articles on medici-
nal plants used for treating diabetes and its co-
morbidities, as well as mechanisms of natural
products as antidiabetic agents. Inhibition of α-
glucosidase and α-amylase, effects on glucose
uptake and glucose transporters, modification of
mechanisms mediated by the peroxisome prolif-
erator-activated receptor, inhibition of protein
tyrosine phosphatase 1B activity, modification of
gene expression, and activities of hormones in-
volved in glucose homeostasis such as adiponec-
tin, resistin, and incretin, and reduction of oxida-
tive stress are some of the mechanisms in which
natural products are involved. We also review
the most relevant clinical trials performed with
medicinal plants and natural products such as
aloe, banaba, bitter melon, caper, cinnamon, co-
coa, coffee, fenugreek, garlic, guava, gymnema,
nettle, sage, soybean, green and black tea, turmer-
ic, walnut, and yerba mate. Compounds of high
interest as potential antidiabetics are: fukugetin,
palmatine, berberine, honokiol, amorfrutins, tri-
gonelline, gymnemic acids, gurmarin, and phlori-
zin.
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!
AMPK: AMP-activated protein kinase
CAP: c-Cbl-associated protein
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NF-κB: nuclear factor-κB
PPAR: peroxisome proliferator-activated
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PTP1B: protein tyrosine phosphatase 1B
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d.Introduction
!
Diabetes is a chronic disease, which if not treated
properly, generates serious complications that re-
duce patientsʼ quality of life and raises the cost of
their care [1]. Its prevalence is increasing steadilyRíos JLworldwide, and it is estimated that by 2025, 300
million people in theworldwill be affected by thiset al. Natural Products for… Planta Med 2015; 81: 975–994t
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d.illness. It is a disease strongly associated with both microvascular
and macrovascular complications, whose pathophysiological
mechanisms are diverse and sometimes unclear [2].
T2DM, a metabolic disease characterized by a persistent increase
in blood glucose above normal values (hyperglycemia) due to a
progressive insulin secretory defect on the background of insulin
resistance [3], is the most common form of the disease. In West-
ern countries, it accounts for 90–95% of all cases of diabetes.
T2DM incidence increases from the third decade of age [4].
Chronic hyperglycemia is associated with long-term dysfunction
and failure of different organs (eyes, kidneys, nerves, heart, and
blood vessels) and is usually associated with other cardiovascular
risk factors such as hypertension, overweight/obesity, dyslipide-
mia, and unhealthy lifestyles (e.g., inadequate diet and sedentar-
ism) [5,6].
Worldwide, the care of T2DM patients consumes between 5 and
10% of the budget allocated to the health system due to the high-
er frequency of consultations and hospitalizations, and longer re-
hospitalizations and more complex treatments [7]. The develop-
ment of chronic complications also increases the costs of patient
care [8]. Several studies have shown that actions aimed at pre-
venting these complications are cost effective [9]. Development
of T2DM can be prevented or at least delayed in patients with im-
paired glucose tolerance by implementing lifestyle changes [10]
or the use of therapeutic agents [11–13]. In this sense, changes
in lifestyle have shown to be the most convenient cost-effective
prevention and the lowest incidence of adverse side effects.
T2DM includes individuals who have insulin resistance, as men-
tioned above, and usually relative insulin deficiency. Its develop-
ment shows a gradual transition in which alterations of the pan-
creatic β cell mass and function are preceded by a decreased re-
sponse of peripheral tissues to insulin (insulin resistance). These
individuals, at least initially, do not need insulin treatment to sur-
vive and, in some cases, adequate glycemic control can be
achieved with weight loss, exercise, and/or oral glucose-lowering
agents [14]. However, patients with severe β cell destruction, and
therefore no residual insulin secretion, require insulin for surviv-
al.
The onset of T2DM is preceded by impaired glucose tolerance, in
which the changes described in T2DM are already present,
though to a lesser degree [15,16]. T2DM usually remains undiag-
nosed for many years because hyperglycemia increases gradually
and at earlier stages it is often insufficient for the patient to no-
tice any classic symptoms of the illness.
It is now clear that the paramount condition for developing
T2DM is β cell failure. Although several pathogenic processes are
involved in the development of T2DM (aside from the autoim-
mune destruction of β cells, which does not occur), two basic con-
ditions for abnormalities in carbohydrate, fat, and protein metab-
olism in target tissues of the diabetic patient normally coexist in
the same person: insulin resistance and decreased function and
mass of pancreatic β cells.
Following a meal, insulin promotes carbohydrate uptake at stor-
age sites and drives the conversion of carbohydrates into lipids, a
more efficient means of storage for calories. Interaction between
insulin and its receptor triggers a downstream signalling path-
way that is ultimately responsible for the metabolic effects, in-
cluding thosementioned above, of the hormone on target tissues.
In insulin resistance, this transduction pathway becomes im-
paired, thereby resulting in hampered insulin action. Several
mechanisms have been proposed to explain the pathogenesis of
insulin resistance: ectopic lipid accumulation, endoplasmic retic-Ríos JL et al. Natural Products for… Planta Med 2015; 81: 975–994ulum stress, and activation of unfolded protein response and sys-
temic inflammation. These mechanisms, which reflect the failure
of different aspects of metabolic control, may crosstalk to regu-
late insulin action [17].
A decreased function of pancreatic β cells must be considered
when secretion of insulin in response to a rise in blood glucose
is insufficient to meet the demand (a relative rather than an ab-
solute deficiency) [18].
Impaired β cell function involves three features: decreased sensi-
tivity to glucose, loss of pulsatility and the biphasic nature of in-
sulin secretion, and a decrease in β cell mass. In the first case,
although the normal sensitivity threshold has wide individual
variations not affecting their ability to maintain glucose homeo-
stasis, sensitivity of β cells to glucose decreases progressively
from impaired glucose tolerance to T2DM [19]. In the second
case, biphasic profile and pulsatility are characteristic features
of insulin secretion altered early in T2DM, thus resulting in good
indicators of a progressive decline in β cell function. Secretory
dysfunction of β cells occurs before the onset of clinical manifes-
tations, and other factors such as dyslipidemia, changes in hor-
mone levels and cytokine function, and impairment of endothe-
lial cells and vascular flow, contribute to its development [20]. In
the third case, maintenance of an adequate β cell mass is essential
for controlling blood glucose homeostasis and preventing the de-
velopment of diabetes. Clinical studies clearly show that an inad-
equate β cell mass due to an imbalance between the rate of cell
renewal and apoptosis is observed in T2DM, with autopsies of in-
dividuals with diabetes having shown a 50–60% decrease of β cell
mass, which is already evident at the stage of impaired glucose
tolerance [16]. These results demonstrate that a decrease in β
mass is a progressive process that starts early in the pathogenesis
of T2DM.
Characteristic diabetic hyperglycemia plays an important role in
impairing insulin secretion and β cell mass, a phenomenon called
glucotoxicity that triggers glycooxidation processes. As demon-
strated by Sakura et al., there is a negative correlation between β
cell mass and expression of oxidative stress-related DNA damage
in the islet of patients with T2DM [21]. Another mechanism in-
volved in β cell failure is insular amyloid deposition. Fibrillary de-
generation of amylin in β granules is a process that increases with
age and is markedly increased in people with diabetes [16]. Gly-
cooxidative stress and amyloid deposition can explain the de-
crease in β cell function andmass in diabetic hyperglycemia asso-
ciated with increased endoplasmic reticulum stress in the im-
paired glucose tolerance state. Functional overload of β cells due
to increased demand for the hormone in insulin-resistant states
could be responsible for the activation of endoplasmic reticulum
stress and a consequently increased rate of apoptosis [22].
The aim of this review is to present new findings in phytotherapy
for T2DM, with the objectives focused on novel ethnopharmaco-
logical approaches, recent research on selected plants and iso-
lated compounds, and, especially, recent contributions from clin-
ical trials.Antidiabetics of Plant Origin
!
Throughout history, different remedies and drugs have been used
to treat T2DM, including insulin before knowledge of its mecha-
nism of action. Some of them have been included in the thera-
peutic arsenal of medicine, and others are used as complementa-
ry therapy in patients with hyperglycemia. Several of these com-
Fig. 1 Chemical structures of galegine and metformin.
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d.pounds have been obtained from plants or frommicrobes. Classic
examples are galegine, phenolics compounds and pycnogenol
derived from plants, and acarbose, miglitol, and voglibose from
microbes.
The first medicinal plant describedwith a clear antidiabetic effect
was Galega officinalis L. (Fabaceae), which has been prescribed
since the Middle Age to treat diabetes mellitus. From this plant,
also called goatʼs rue, French lilac, or Italian fitch, a guanidine de-
rivative, galegine, was isolated. This compound, whose chemical
structure is quite similar to the antidiabetic drug metformin, is
responsible for the lowering of blood glucose produced by the
plant extract. The structure of both compounds is shown in
l" Fig. 1 [23,24].
Different phenolic compounds such as flavonoids and antocya-
nins have positive effects on diabetes [25]. For example, different
anthocyanins from Ipomoea batatas (L.) Poir. (Convolvulaceae)
and Pharbitis nil (L.) Choisy (Convolvulaceae) are effective inhib-
itors of intestinal α-glucosidase/maltase activity [26] and can re-
duce glycemia after starch-richmeals. Inhibitory effects of antho-
cyanins depend on their structure, as their potency as α-glucosi-
dase inhibitors is higher in acylated anthocyanins than in deacy-
lated derivatives [23].
A third example of a natural product with antidiabetic properties
is pycnogenol, a patented water extract obtained from French
maritime pine bark (Pinus pinaster Aiton, Pinaceae) rich in poly-
phenols [23]. Antidiabetic properties of pycnogenol are due to its
digestive enzyme inhibitory activity, especially against α-glucosi-
dase [27]. Of the compounds present in the mixture, only (+)-cat-
echin and procyanidins are able to inhibit α-glucosidase. Pycno-
genol also competitively inhibited α-amylases from the human
salivary glands and the porcine pancreas [28]. Pycnogenol
(100mg/day for 3 months) in addition to conventional treatment
with oral antidiabetic drugs reduced blood glucose levels and im-
proved endothelial function in patients with T2DM. Moreover,
this reduction in glycemia was dose dependent without increas-
ing insulin secretion [29,30].
In addition to antidiabetic plant compounds, three examples of
microbial origin may be mentioned. Acarbose (from Actinoplanes
sp.) is probably the most widely used digestive enzyme inhibitor
for the treatment of T2DM, acting on α-glucosidase, α-amylase,
sucrase, and maltase, but without insulinotropic properties [23,
31,32]. Miglitol is a second-generation α-glucosidase inhibitor
structurally similar to glucose. Originally obtained from various
Bacillus and Streptomyces strains, it is now obtained by the oxida-
tion of 1-amino-D-sorbitol to 6-amino-L-sorbose by fermenta-
tion using Gluconobacter oxydans [23]. Voglibose is synthesized
from valiolamine, which is isolated from a fermentation broth of
Streptomyces hydroscopicus subsp. limoneus [33]. It is also an α-
glucosidase inhibitor, which competitively and reversibly inhibits
glucoamylase, sucrase, and isomaltase but has no activity on α-
amylases. It also reduces plasma glucose levels and insulin in a
dose-dependent manner [23,34].
An interesting point to consider is herbal drug standardization.
In-depth analysis of each step during the preparation of samples
is necessary in order to ensure quality, safety, and reproducibil-
ity. With this objective, Chawla et al. [35] proposed a model for
developing these challenges in clinical studies, and suggested
further studies to guarantee effective herbal drug standardiza-
tion methodology, as well as a regulatory standard guide for fu-
ture research.Recent Reviews on Antidiabetic Medicinal Plants
!
In recent years, many reviews focusing on natural products and
medicinal plants with antidiabetic potential have been published.
For example, Hays et al. [36] reviewed the role of natural prod-
ucts and pharmacological interventions in the prevention and
treatment of T2DM. Nahas and Moher [37] reviewed some rele-
vant medicinal plants and their potential as antidiabetics, includ-
ing clinical trials. Bedekar et al. [23] compiled data on natural
products for T2DM treatment. Patel et al. analyzed pharmacolog-
ical aspects of antidiabetic properties and compiled data con-
cerning 37 species in a first study [38] and 68 species in a second
revision [39]. Chang et al. [40] reviewed mechanisms of antidia-
betic action and herbal therapies for T2DM and their potential
applications. El-Abhar and Schaalan [41] analyzed potential
mechanisms in phytotherapy and their possible clinical applica-
tions. Finally, Eddouks et al. [42] compiled 111 antidiabetic me-
dicinal plants that can improve insulin sensitivity, selecting 31
with a high potential for future studies due to their important
role in controlling insulin resistance associated with diabetes
mellitus.
In other types of reviews, the authors focused their efforts on
compiling antidiabetic medicinal plants from different parts of
the world in function of their ethnopharmacogical use (l" Table
1).
This review will focus on recent studies, especially relevant con-
tributions that involved clinical trials.Mechanisms of Natural Products as
Antidiabetic Agents
!
Different authors have focused their studies on themechanism of
action of principles isolated from medicinal plants with antidia-
betic properties. For example, Tabatabaei-Malazy et al. [66] re-
viewed the effects of the main component of antidiabetic plants
with direct action on insulin secretion from the pancreas. They
established that improvement of β cell function and insulin se-
cretion is possible with antioxidant compounds via suppression
of oxidative stress, although other mechanisms are also impor-
tant such as cytokine-induced impairment, suppression of NF-
κB, activation of uncoupling protein 2, insulin-like activity, and
increasing intracellular calcium. These authors compiled the ef-
fects of different agents but did not establish the mechanism of
each compound. El-Abhar and Schaalan [41] also reviewed the
potential mechanisms of natural products as antidiabetic agents.
They established different points with potential such as inhibi-
tion of glucose absorption in the gut, enhancement of glucose up-
take and upregulation of glucose transports, activation of nuclear
receptors, increasing adiponectin release, modification of glyco-
gen metabolism, insulinomimetic and insulinotropic effects, ele-Ríos JL et al. Natural Products for… Planta Med 2015; 81: 975–994
Fig. 2 Chemical structures of vasicine, vasicinol, and andrographolide.
Table 1 Relevant reviews on anti-
diabetic medicinal plants from dif-
ferent parts of the world in func-
tion of their ethnopharmacogical
use.
Ethnopharmacological criteria used Country Ref.
Antidiabetic herbal drugs officially approved China [43]
Antidiabetic plants Iran [44–46]
Antidiabetic plants with α-glucosidase activity Mexico [47,48]
Medicinal plants with antidiabetic potential India [49,50]
Antidiabetic interventions in Ayurvedicmedicine India [51]
Antidiabetic medicinal Pakistan [52]
Medicinal plants used formanagement of T2DM Bangladesh [53,54]
Plant species used as antidiabetics India, Pakistan, Sri Lanka [55]
Medicinal plants used in diabetes Guinea [56]
Antidiabetic plants with α-glucosidase activity Philippines [57]
Plants used against diabetes in Kisangani City DR Congo [58]
Ethnomedicinal native remedies used in diabetes Mauritius [59,60]
Traditional medicinal plants used in diabetes Nigeria [61]
Plants with antidiabetic potential used in African Africa [62]
Medicinal plants used in diabetes Morocco [63]
Antidiabetic medicinal plants Jordan [64]
Antidiabetic remedies from Limamarket Peru [65]
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d.vation of D-chiro-inositol, incretin mimetic and incretin en-
hancers, roles of endogenous opioids on glucose homeostasis,
and antioxidants. New types of antidiabetic drugs have been in-
troduced in treatments in recent years, such as DDP-4 inhibitors,
GLP-1 analogs, and cannabinoid receptor type 1 antagonists. Sev-
eral studies reported that some natural products could act by
these mechanisms.
Inhibition of α-glucosidase and α-amylase
in the digestive tract
As mentioned above in the Antidiabetics of Plant Origin section,
inhibition of α-glucosidase activity was demonstrated as a good
strategy for controlling glycemia and in consequence, glucosidase
inhibitors have been used in medicine for diabetes treatment.
Even though the use of acarbose, the principal drug of this group,
is now restricted due to its low efficacy in decreasing glycemia
and unpleasant side effects, neither of which are well accepted
by both patients and physicians, various researchers focused
their studies on different plant extracts containing glucosidase
inhibitors without these side effects. For example, Ramírez et al.
[47] screened the inhibitory effect of hydroethanolic extracts
from 23 medicinal plants used in Mexico as antidiabetics on glu-
cosidase obtained from rat intestinal mucosa. Camellia sinensis
(L.) Kuntze (Theaceae) displayed the highest inhibitory activity
(85%, IC50 299 µg/mL), followed by Ludwigia octovalvis (Jacq.)
P.H. Raven (Onagraceae) and Iostephane heterophylla (Cav.)
Benth. Ex Hemsl. (Asteraceae) (83%, IC50 202 µg/mL and 61%,
CI50 509 µg/mL, respectively). Although the authors confirmed
that the major compounds in the active species are catechins, fla-
vonols, flavones, and caffeoyl derivatives, they proposed more
phytochemical assays to detect other active principles.
El-Abhar and Schaalan [41] reviewed and compiled different spe-
cies with effects on glucose absorption in the gut. Some well-
known species, such as Adathoda vasicaNees (Acanthaceae), have
sucrose inhibitory activity, with vasicine and vasicinol (l" Fig. 2)
as potential active phytochemicals, which may be of interest for
the future development of new α-glucosidase inhibitory agents.
Andrographolide (l" Fig. 2) from Andrographis paniculata (Burn.
f.) Nees (Acanthaceae) could be another interesting active princi-
ple as was demonstrated in vitro using porcine α-amylase
(IC50 = 11.3 ± 0.29mg/mL) and in vivo (10mg/kg) using diabetic
rats as well as pycnogenol from P. pinaster. Fenugreek seeds (Tri-
gonella foenum-graecum L., Fabaceae) inhibit intestinal glucosi-Ríos JL et al. Natural Products for… Planta Med 2015; 81: 975–994dase in diabetic rats (standard laboratory chow supplemented
with 20% fenugreek), and have a positive effect on glucolytic and
gluconeogenic enzymes to restore glucose homeostasis [41].
Inhibition of α-amylase is a possibility for treating T2DM by phy-
totherapy. Amylase inhibitors retard the liberation of glucose
from carbohydrates, delaying its intestinal absorption and conse-
quently postprandial glycemia, thus reducing hyperglycemia
[67]. In this sense, Melzig and Funke [68] studied the possible
use of α-amylase inhibitors from medicinal plants in a supple-
mentary treatment of diabetes. They suggest a rational therapy
with traditional herbal preparations and clinical studies, and
propose the use of blueberry (leaves), tamarind, lemon balm,
rosemary, white kidney beans (hulls), and green tea. Rahimzadeh
et al. [69] tested two aqueous leaf extracts from Urtica dioica L.
(Urticaceae) and Juglans regia L. (Juglandaceae) for α-amylase in-
hibition in vitro using acarbose as the standard inhibitor. Both
plant extracts showed time- and concentration-dependent com-
petitive inhibition of α-amylase, with the extract from J. regia
(0.4mg/mL) being more active than U. dioica (2mg/mL). In the
same sense, Picot et al. [60] tested five medicinal plants as poten-
tial inhibitors of α-amylase in vitro, but only three of them
showed activity: Erythroxylum laurifolium Lam. (Erythroxyla-
ceae), Elaeodendron orientale Jacq. (Celastraceae), and Antidesma
madagascariensis Lam. (Euphorbiaceae), with IC50 values of 7.5,
Fig. 3 Chemical structures of palmatine, honokiol, amorfrutin 1, amor-
frutin B, and amorphastilbol.
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d.1.7, and 2.2mg/mL, respectively. Another interesting study fo-
cused on the search for new inhibitions of α-amylase contained
endophytic actinomycetes from leaves and stems of medicinal
plants such as Leucas ciliata Benth. (Lamiaceae) and Rauwolfia
densiflora (Wall) Benth. ex HK.f (Apocynaceae) [67]. The authors
justified their experiments as a goodmodel for finding new sour-
ces of antidiabetic agents.
For the same purpose, Li et al. [70] recently investigated and es-
tablished a ligand screening method based on enzyme-immobi-
lized magnetic nanoparticles integrated with HPLC for studying
new α-amylase inhibitors of plant origin. The authors isolated
three potential agents from extracts of Garcinia xanthochymus
Hook.f. (Clusiaceae), which were identified as the bioflavonoids
fukugetin, GB2a, and GB2a glucoside. Fukugetin and GB2a gave
IC50 values of 0.97 µg/mL and 3.46 µg/mL, respectively, whereas
the antidiabetic standard drug used, acarbose, showed an IC50
value of 9.04 µg/mL. The potency of the GB2a glucoside was
clearly lower than the aglycones tested.
Effects on glucose uptake and glucose transporters
In a physiological process in myocytes and adipocytes, insulin in-
duces the activation of the insulin receptor, which leads to the re-
cruitment of IRS proteins followed by activation of phosphatidyl
inositol 3 kinase and subsequent translocation of GLUT4 to the
plasma membrane and glucose uptake [71]. Different agents tar-
geted this process. For example, a 70% ethanol extract (10 µg/mL)
from Tinospora cordifolia (Willd.) Miers ex Hook.f. & Thomson
(Menispermaceae) and its major compound palmatine (625 nM)
(l" Fig. 3) induced overexpression of GLUT-4 up to 5- and 4-fold,
respectively. On account of these results, the authors hypothesize
that these medicinal plants and palmatine activity are majorly
mediated through the insulin pathway [72].
Kadan et al. [73] screened eight medicinal plants used for treat-
ing diabetes and tested the effects of the 50% ethanol plant ex-
tract on a GLUT4 translocation assay. The extracts were added to
L6-GLUT4myc cells in the presence or absence of insulin. Their
results indicate that four of the eight plants, T. foenum-graecum,
U. dioica, Atriplex halimus Ritter ex Moq. (Chenopodiaceae), and
Cinnamomum verum J.Presl (Lauraceae), induce a significant in-
crease in GLUT translocation, thus suggesting that the antidia-
betic properties of these plants are mediated, at least partially,
through regulation of this process. However, these results should
be taken with caution since the study involved muscle cells over-
expressing GLUT4.
El-Abhar and Schaalan [41] described different medicinal plants
that upregulate GLUT4 expression or increase its translocation.
As relevant antidiabetic plants with active principles, they cited
Cecropia obtusifolia Bertrol (Cecropiaceae) and chlorogenic acid,
Momordica charantia L. (Cucurbitaceae), Lagerstroemia speciosa
(L.) Pers. (Lythraceae) and corosolic acid, A. paniculata and andro-
prapholide, and Panax ginseng C.A.Meyer (Araliaceae) and ginse-
noside Rh2.
Some of these mechanisms are mediated by PPAR. PPARs are a
group of three nuclear receptor isoforms (PPARγ, PPARα, and
PPARδ) encoded by different genes (PPARG and others). Ligand-
regulated transcription factors, they control gene expression
(such as CAP and GLUT4) by binding to specific response elements
within promoters [74].
Human PPARα is expressed in several metabolically active tissues
including liver, kidney, heart, skeletal muscle, and brown fat. It is
also present in monocytic, vascular endothelial, and vascular
smooth muscle cells. PPARα plays a critical role in the regulationof cellular uptake, activation, and oxidation of fatty acids, and in-
duces expression of two proteins that transport fatty acids across
cell membranes. Thus, an increase in PPARα expression can pre-
vent some risk factors and have a net benefit to improvemetabol-
ic outcomes.
PPARγ plays a relevant role in controlling cellular energy homeo-
stasis. Induced during the differentiation of preadipocytes into
adipocytes, it plays an important role in lipid metabolism, but al-Ríos JL et al. Natural Products for… Planta Med 2015; 81: 975–994
Fig. 4 Chemical structures of epigallocatechin gallate, carnosol, carnosic
acid, isoliquiritigenin, 2′,4′-dimethoxy-4-hydroxychalcone, and liquiritige-
nin-7,4′-dibenzoate.
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d.so in other pathways such as inflammation, immunity, and glu-
cose homeostasis. Specifically, PPARγ controls the expression of
several factors secreted from adipose tissue that influence insulin
sensitivity positively, such as adiponectin and leptin, or nega-
tively, such as resistin and TNF-α. Also, in differentiated adipo-
cytes, PPARγ can directly modulate the expression of genes in-
volved in glucose homeostasis, e.g., it upregulates GLUT4 and
CAP, which are encoded by GLUT4 and c-CAP genes, respectively
[75]. Some previous reports established that this could be the
mechanism of antidiabetic action of plants such as pomegranate
(Punica granatum L., Lythraceae), which is used in traditional folk
medicines of India. The authors cited the possible involvement of
oleanolic, ursolic, and gallic acids in this mechanism [76]. In addi-
tion, Wang et al. [75] extensively reviewed medicinal plants and
their isolated compounds with effects on PPARγ activation and
cited 45 medicinal plants and 20 natural products, such as hono-
kiol, amorfrutin 1, amorfrutin B, and amorphastilbol (l" Fig. 3), as
potential therapeutic agents to counteract metabolic syndrome
and T2DM [75]. For example, honokiol binds to purified human
PPARγ (Ki = 22.9mM), activating PPARγ-dependent reporter gene
expression as a partial agonist (EC50 = 3.9 µM) and induces glu-
cose uptake but not adipogenesis in 3 T3-L1 cells (at 1–10 µM).
In in vivo experiments, honokiol decreased blood glucose levels
in diabetic KKAy mice with simultaneous suppression of weight
gain. For the other three compounds, Ki values of binding to pu-
rified human PPARγ were 0.24 µM, 0.019 µM, and 0.85 µM, re-
spectively [76].
Sangeetha et al. [72] studied the effects of T. cordifolia and one of
its major compounds, palmatine, on the expression of PPARα and
PPARγ. Whereas the first transcription factor is upregulated by
both the extract and alkaloid, the second is downregulated by T.
cordifolia and palmatine, 0.67- and 0.38-fold, respectively. The
moderate upregulation of PPARα expression could in part justify
medicinal use of this plant.
Green tea (C. sinensis) and its epigallocatechin gallate-enriched
extract (l" Fig. 4) improved glucose homeostasis and increased
the expression of PPARγ in a fructose fed insulin-resistant ham-
ster model. Clematis pickeringii A.Gray (Ranunculaceae) activated
the expression of both PPARα and PPARγ in HepG2 cells. Hono-
kiol, the active principle ofMagnolia officinalis Rehder & E.H.Wil-
son (Magnoliaceae), stimulated basal glucose uptake and acted as
a partial agonist of PPARγ (in silico and in vitro studies). In a fusion
receptor of the yeast Gal4-DNA binding study, rosemary (Ros-
marinus officinalis L., Lamiaceae) and sage (Salvia officinalis L.,
Lamiaceae) are activators of human PPARγ. Their active principles
could be carnosol and carnosic acid, which gave EC50 values of
41.2 ± 5.9 µM and 19.6 ± 2.0 µM, respectively [41].
Isoliquiritigenin and liquiritigenin isolated from Glycyrrhiza gla-
bra L. (Fabaceae) rhizomes and nine derivatives were screened in
an oral glucose tolerance test in normal Swiss albino male mice.
Seven out of eleven tested compounds showed a significant blood
glucose-lowering effect. The structure-activity relationship indi-
cated that ether and ester groups present in these compounds are
relevant for this activity. Isoliquiritigenin, 2′,4′-dimethoxy-4-hy-
droxychalcone and liquiritigenin-7,4′-dibenzoate (l" Fig. 4) were
selected to evaluate their in vivo antidiabetic activities at 200,
50, and 50mg/kg bw, respectively, andwere found to be potential
candidates for treating diabetes. A previous study demonstrated
that chalcone derivative antidiabetic activity is mediated via
stimulation of PPARγ, and that flavonoids modify activity of in-
tracellular enzymes such as glucosidases [77].Ríos JL et al. Natural Products for… Planta Med 2015; 81: 975–994Adiponectin is a protein exclusively secreted by adipocytes (col-
lectively called adipokines). Epidemiological studies revealed
that patients with diabetes have a lower circulating level of adi-
ponectin compared with nondiabetic subjects, thus a low level
of this adipokine can be an excellent predictor of developing
Fig. 5 Chemical structures of phlorizin, sergliflozin, and dapagliflozin.
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such as I. batatas, Aronia melanocarpa (Michx.) M.Roem (Rosa-
ceae), and Salacia reticulataWight (Celastraceae), as well as from
the mushroom Agaricus blazei Murill (Agaricaceae), act to in-
crease adiponectin release.
PPARγ also controls expression of resistin from adipose tissue,
which influences insulin sensitivity negatively. Different plant
extracts and natural products couldmodify the expression of this
hormone. Studies with Rehmannia glutinosa Steud. (Scrophular-
iaceae) [78], Lysimachia foenum-graecum Hance (Primulaceae)
[79], and Garcinia cambogia Roxb. (Clusiaceae) [80] demonstrat-
ed significant reductions in glucose intolerance and the plasma
resistin level in treated diabetic mice. However, in this last study,
an increase in hepatic collagen accumulation, lipid peroxidation,
and cytokine expression was observed. These changes could
cause liver inflammation and, in consequence, a potential non-
desirable effect. In the case of isolated compounds, trigonelline
[81] and oleanolic acid [82] attenuated resistin expression via
the downregulation of its gene expression (ADIPOQ).
Another point to be considered in the research of antidiabetic
medicinal plants in the near future is the study of new antidia-
betic agents and new targets for these compounds. For example,
the potential effects of the bark of apple trees was reported for
the treatment of T2DM as SGLT2 inhibitors, because inhibition
of this system could be as efficient as other oral hypoglycemic
drugs [83]. However, more highly interesting seems to be the
studies of Makarova et al. [84] who analyzed health-promoting
properties of apples (Malus domestica Borkh., Rosaceae) and
phlorizin-enriched powder derived from unripe apples as poten-
tial antihyperglycemic agents in healthy volunteers. The unripe
apple preparations have 12.6 g/kg of phlorizin. Acute ingestion
of the apple preparation improved glucose metabolism in the
oral glucose tolerance test by reducing the postprandial glucose
response approximately two-fold after 15 to 30min and by in-
creasing urinary glucose excretion fivefold during the 2 to 4 h
interval of the test [84]. Because phlorizin is a competitive inhib-
itor of SGLT1 (which contributes to renal glucose reabsorption in
the small intestine) and SGLT2 (which contributes to glucose
reabsorption in the small intestine and nephron), it reduces renal
glucose transport, thus lowering glycemia. Some semisynthetic
analogs have been introduced in therapeutic treatments as po-
tential antidiabetic agents, as is the case of sergliflozin, remogli-
flozin, canagliflozin, and dapagliflozin [85], thus illustrating an
excellent way for discovering new active compounds, especially
in the field of antidiabetic drugs (l" Fig. 5).
Enhancers of insulin secretion and
pancreatic β cell proliferation
Incretins are gut-derived hormones released in response to nu-
trient ingestion, principally glucose and fat [86]. They are mem-
bers of the glucagon superfamily and stimulate pancreatic insulin
secretion in a glucose-dependent manner. There are two gut hor-
mones with an incretin effect, the GIP secreted by L-cells of the
distal ileum and colon, and GLP-1 secreted by K-cells in the duo-
denum and jejunum. Both GLP-1 and GIP are rapidly inactivated
by the enzyme DPP-4 [87]. In consequence, inhibition of DPP-4 to
extend GLP-1 half-life or usage of GLP-1 analogs resitant to DDP-
4 degradation are two very well-recognized strategies to find
antidiabetic compounds. Different inulin-type fructans
(l" Fig. 6), such as those obtained from Cichorium intybus L. (As-
teraceae) and Agave tequilana F.A.C.Weber (Agavaceae), enhance
colon production of GLP-1 [41], whereas Pterocarpus marsupiumRoxb. (Leguminosae), Eugenia jambolana Lam. (Myrtaceae), Ago-
nia cretica L. (Zygophyllaceae), and Hedera nepalensis K.Koch
(Araliaceae) inhibit DPP-4.
Kosaraju et al. [88] tested three antidiabetic plants and demon-
strated that P. marsupium and E. jambolana inhibited DPP-4. The
third species, Gymnema sylvestre (Retz.) R.Br. ex Sm. (Asclepiada-
ceae), showed a limited effect in this test. Active extracts signifi-
cantly increased GLP-1 levels with a peak at 2 h. However, Saleem
et al. [89] with Fagonia cretica L. (Zygophyllaceae) and H. nepal-
ensis showed a greater effect as DDP-4 inhibitors, with IC50 values
in the range of 17.2 to 34.4 µg/mL versus 273.7 to 773.2 µg/m, re-
spectively, values higher than those obtained in the case of plants
studied by Kosaraju et al. [88]. Four compounds were identified,
three from F. cretica (quinovic acid glycosides,l" Fig. 6), which in-
hibited DPP-4 activity (IC50 30.7–57.9 µM), and one from H. nep-
alensis, the triterpene lupeol (IC50 31.6 µM) [89].
Harmine is the major alkaloid from Peganum harmala L. (Zygo-
phyllaceae). It is a competitive inhibitor of ATP binding to the ki-
nase pocket of dual-specificity tyrosine-regulated kinase-1a
(DYRK1A) and it likely acts as a mediator of human β cell prolifer-
ation and differentiation, but harmine can also inhibit other
DYRK family members, monoamine oxidases (MAO), and cdc-like
kinases (CLK). In order to avoid these secondary effects, Wang et
al. [90] studied different harmine analogs with therapeutic inter-
est, and obtained that INDY, a chemical compound that inhibits
DYRK1A but not MAO, activated proliferation in human β cells,
whereas harmaline and harmane are inhibitors of MAO but not
DYRK1A and did not induce proliferation. The authors concluded
that harmine analogs could be a good source of DYRK1A inhib-
itors with interest for obtaining new antidiabetic agents.Ríos JL et al. Natural Products for… Planta Med 2015; 81: 975–994
Fig. 7 Chemical struc-
tures of chlorogenic ac-
id, 3-p-coumaroylquinic
acid, trihydroxynaph-
thalene-hexoside,
kaempferol-glycosides,
and quercetin-glyco-
sides.
Fig. 6 Chemical struc-
tures of inulin-type
fructans and quinovic
acid glycosides.
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PTP1B negatively regulates the insulin-signaling pathway. This
enzyme could be a promising therapeutic target for T2DM treat-
ment [91].
Uddin et al. [92] studied the effects of an ethyl acetate-soluble ex-
tract of Camellia japonica Wall. (Theaceae) fruit peels together
with ten triterpenoids isolated from this plant. Although the
study focused on potential anticancer agents in human breast
cancer cell lines, the effects of these compounds as PTP1B inhib-
itors and their chemical structure-activity relationship were es-
tablished. The PTP1B inhibitory activity range (IC50 values) was
from 3.77 to 6.40 µM.
The air-dried green leaves of walnut (J. regia) are used to treat di-
abetic symptoms in folk medicine. Their leaf methanolic extract
enhanced glucose uptake in myocytes by inhibition of PTP1B but
had no effect as a PPARγ agonist. The main compounds identified
in this extract were chlorogenic acid, 3-p-coumaroylquinic acid,
and a trihydroxynaphthalene-hexoside as well as eight flavonoid
glycosides derived from kaempferol and quercetin (l" Fig. 7) [93].
Oxidative stress, diabetes, and antioxidants
The metabolic abnormalities of diabetes cause mitochondrial
superoxide over-production in several tissues including the en-
docrine pancreas, which in turn activates pathways involved in
the pathogenesis of complications and a further increase in intra-
cellular reactive oxygen species (ROS) [94]. Therefore, ROS seem
to be causal agents in the pathogenesis of diabetes by damaging β
cells. However, the removal of too many ROS may itself lead to
metabolic dysfunction and predisposition to diabetes [95]. Con-
sequently, since oxidative stress plays a key role in insulin resis-
tance and β cell dysfunction, administration of antioxidants could
help to reduce diabetic complications, but it should be considered
that a drastic reduction of radicals such as NO after an antioxi-
dant therapy could be implicated in future cardiovascular dis-
eases associated with diabetes. Therefore, different studies wereRíos JL et al. Natural Products for… Planta Med 2015; 81: 975–994oriented towards this goal. Some examples of species with posi-
tive effects are compiled in l" Table 2 [41].
Palma et al. [96] evaluated the effects of curcumin (l" Fig. 8) and
insulin on antioxidant enzyme activity in blood, liver, and kidney
as well as on lipid peroxidation in rats. Histopathological analysis
showed that treatment with insulin improved renal and hepatic
lesions from both the diabetic insulin-treated group and the dia-
betic insulin/curcumin-treated group, as well as thiobarbituric
acid reactive substance levels in serum, liver, and kidney of the
treated groups. Rats treatedwith curcumin and insulin presented
an increase in catalase activity, revealing a positive interaction
between both substances. This treatment also prevented the oxi-
dative stress in blood, which was reduced through the modula-
tion of enzymatic antioxidant defenses [96].
Otostegia persica Boiss (Lamiaceae) significantly decreased glyce-
mia in diabetic rats 1–4 h after treatment, parallel to an increase
in the serum insulin level. This extract also significantly de-
creasedMDA and increased GSH levels in the liver of diabetic rats.
The authors identified thymol (l" Fig. 8) as the major compound
in the active extract [97].
Cyanidin-3-O-β-D-glucopyranoside (l" Fig. 8) from mulberry
(Morus alba L., Moraceae) fruits has protective effects against ox-
idative damage in streptozotocin-induced diabetic rat bladder
[98]. Achyranthes aspera Duss (Amaranthaceae) ethanolic ex-
tracts showed antioxidant activity and significantly reduced
blood glucose levels in alloxan-induced diabetic mice. This ex-
tract also prevented lipid peroxidation and hydroperoxides, in-
creased catalase activity, and reduced nitric oxide levels in the
Table 2 Plants with positive effects in experimental diabetes mellitus through
their antioxidant properties [41].
Plant species Family
Acanthopanax senticosusHarms Araliaceae
Albizia lebbeck (L.) Benth. Mimosaceae
Allium sativum L. Alliaceae
Amaranthus esculentus Besser Amaranthaceae
Aralia taibaiensis Z.Z.Wang & H.C.Zheng Araliaceae
Azadirachta indica A.Juss. Meliaceae
Camellia sinensis (L.) Kuntze Theaceae
Capparis decidua Edgew. Capparaceae
Emblica officinalisGaertn. Euphorbiaceae
Ficus carica L. Moraceae
Ficus bengalensis L. Moraceae
Gentiana olivieri Griseb Gentianaceae
Lycium barbarum Lam. Solanaceae
Momordica charantia L. Cucurbitaceae
Morinda officinalis F.C.How Rubiaceae
Musa × sapientum L. Musaceae
Ocimum sanctum L. Lamiaceae
Panax ginseng C.A.Meyer Araliaceae
Phyllanthus amarus Schumach. Euphorbiaceae
Plantago depressaWilld. Plantaginaceae
Pueraria lobata (Willd.) Ohwi Fabaceae
Punica granatum L. Lythraceae
Scutellaria baicalensis Georgi Lamiaceae
Silybummarianum (L.) Gaertn. Asteraceae
Strobilanthes crispa T. Anderson Acanthaceae
Vaccinium arctostaphylos L. Ericaceae
Fig. 8 Chemical structures of curcumin, thymol, cyanidin-3-O-β-D-gluco-
pyranoside, berberine, apocynin, and lipoic acid.
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d.same experiments. The authors conclude that antihyperglycemic
activity of A. aspera extracts could be mediated by oxidative
stress reduction [99]. The methanolic extract of Picralima nitida
Th. & H.Dur. (Apocynaceae) and the hydroethanolic extract of
Sonchus oleraceus Wall. (Asteraceae) showed significant antidia-
betic activities, with a 39% reduction in glycemia, a significant re-
duction in MDA and hydrogen peroxide levels, and a substantial
increase in catalase activity [100]. Murraya koenigii Spreng. (Ru-
taceae) and Olea europaea L. (Oleaceae) reduced serum glucose
levels by 56% and 67%, respectively, compared to the metformin
group (63%). The authors hypothesized that antioxidants such as
carbazole alkaloids and polyphenols in the extract could be re-
sponsible for this activity [101].
Berberine (l" Fig. 8) is an alkaloid found in different medicinal
plants such as Berberis vulgaris L. (Berberidaceae), Coptis chinen-
sis Franch. (Ranunculaceae), and Hydrastis canadensis. Poir. (Ra-
nunculaceae). It showed antioxidant activity due to its scavenger
properties against superoxide free radicals, an increase of sirtuin
1 expression, and attenuation of nicotinamide adenine dinucleo-
tide phosphate (NADPH) oxidase expression. Activation of
NADPH oxidase is associated with diabetes, and is now consid-
ered a potential target to treat the illness and related complica-
tions. Therefore, inhibition of NADPH oxidase could partially ex-
plain the beneficial effects of berberine on diabetic complica-
tions. Inflammation is also critical for the pathogenesis of T2DM,
and berberine has shown anti-inflammatory properties, prob-
ably due to its capacity to inhibit mediators and transcription fac-
tors such as TNF-α, IL-6, IL-1β,matrix metalloproteinase-9, cyclo-
oxygenase-2, iNOS, AMPK, MAPK, nuclear factor erythroid 2-re-
lated factor 2 pathway, and NF-κB pathway, which reduced the
inflammatory response in T2DM. In conclusion, berberine anti-oxidant and anti-inflammatory activities could contribute to its
therapeutic efficacy against T2DM and insulin resistance [102].
Apocynin and lipoic acid (l" Fig. 8) are compounds with high po-
tential as antidiabetic agents. Both compounds are widely dis-
tributed in the plant kingdom, and could be the active principles
in studied or not yet investigated medicinal plants. Lipoic acid is
common in plants of the Brassicaceae family (broccoli and water-
cress) but also in spinach and potatoes, whereas apocynin is com-
mon in Picrorhiza kurroa Royle ex Benth. (Scrophulariaceae) but
also in other medicinal plants such as Jatropha multifida L. (Eu-
phorbiaceae) and Apocynum cannabinum L. (Apocynaceae). Cas-
tro et al. [103] demonstrated that lipoic acid prevented hyperin-
sulinemia, hypertriglyceridemia, and insulin resistance, and im-
proved hepatic insulin sensitivity and glucose tolerance. In the
case of apocynin, these authors [104] also demonstrated the role
of NADPH oxidase in fructose-rich diet-induced hepatic oxidativeRíos JL et al. Natural Products for… Planta Med 2015; 81: 975–994
Fig. 9 Chemical struc-
tures of aloesin and co-
rosolic acid.
984 Reviewsstress and metabolic changes, and their prevention by apocynin
coadministration. They concluded that inhibition of NADPH oxi-
dase by apocynin prevents changes in plasma and liver function-
ality, and might become a useful tool for the prevention and
treatment of T2DM.Th
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and Natural Products
!
The number of clinical trials carried out with medicinal plants as
antidiabetic agents are quite limited and some of them are devel-
oped with herbal formulation [105–110]. Other studies include
specific medicinal plants or extracts, and measure some charac-
teristic parameter, such as glycated hemoglobin (HbA1c) in pa-
tients with T2DM [108]. However, all of these studies were of
poor quality with unclear methods of randomization, threats to
blinding, and lack of baseline demographics.
In recent years, some interesting articles on natural antidiabetics,
including medicinal plants used in folk medicine and phytother-
apy, have been reported. Among these plants, bitter melon
(M. charantia), nettle (U. dioica), sage (S. officinalis), and walnut
tree (J. regia) are widely used in folk medicine and some clinical
studies were also developed.
Aloe
Vogler and Ernst [109] reviewed antidiabetic properties of Aloe
barbadensis Mill., syn: Aloe vera (L.) Burm.f., (Aloaceae) and se-
lected a study with 72 diabetic women without drug therapy, di-
vided into two groups. They received A. vera gel (15 g) or placebo
for 42 days. Blood glucose levels subsequently decreased from
250mg to 141mg/dL in the experimental group. The same re-
search team investigated the effects of A. vera gel in combination
with a standard oral antidiabetic therapy (2 × 5mg oral glibencla-
mide) and the subjects received either Aloe or placebo as above.
Results showed similar decreases in blood glucose in the actively
treated group as described in the first trial. However, these stud-
ies were neither randomized nor blinded to patient or investiga-
tor.
Devaraj et al. [110] designed a double-blind, placebo-controlled
pilot study of two Aloe products (UP780 and AC952) in patients
with prediabetes over an 8-week period. A group of 45 subjects
with impaired fasting glucose or impaired glucose tolerance was
recruited. Parameters such as fasting glucose, insulin, homeosta-
sis model assessment (HOMA), HbA1c, fructosamine, oral glucose
tolerance test, and oxidative stress (urinary F2-isoprostanes)
weremeasured along with lipid profile and high-sensitivity C-re-
active protein levels before and after supplementation. Com-
pared to the placebo, only the AC952 A. vera inner leaf gel powder
resulted in a significant reduction in glucose and fructosamine. In
the UP780 A. vera inner leaf gel powder standardized with 2%
aloesin group (l" Fig. 9), there were significant reductions in
HbA1c, fructosamine, fasting glucose, insulin, and HOMA. Only
the UP780 aloe group had a significant reduction in F2-isopros-
tanes compared to placebo group. After evaluation of these re-
sults, the authors considered that standardized aloe preparations
offer an attractive adjunctive strategy to revert impaired fasting
glucose and impaired glucose tolerance observed in conditions
of prediabetes/metabolic syndrome.
Choi et al. [111] studied the metabolic effects of an A. vera gel
complex (Aloe QDM complex, composed of processed A. vera gel
147mg and aloesin powder 3mg) on subjects with prediabetes orRíos JL et al. Natural Products for… Planta Med 2015; 81: 975–994early T2DM. They determined the effects of the Aloe QDM com-
plex on fasting blood glucose, fasting serum insulin, and HO-
MA‑IR in obese individuals (n = 136) with prediabetes or early
diabetes mellitus without medical treatment. After 4 weeks, the
serum insulin level and HOMA‑IR were lower in the intervention
group. They also were lower after 8 weeks, but with borderline
significance. They concluded that in obese individuals with pre-
diabetes or early-untreated T2DM, Aloe QDM complex reduced
insulin resistance as well as other parameters such as body
weight and body fat mass.
Banaba
The hypoglycemic effects of banaba (L. speciosa) have been attrib-
uted to both corosolic acid (l" Fig. 9) and ellagitannins [112]. To
ratify these properties and active principles, different studies
were run in vitro in animal models and in human beings using
water-soluble banaba leaf extracts (100mg), corosolic acid-stan-
dardized extracts (60mg containing 10mg corosolic acid/2
weeks), and purified corosolic acid (10mg/30 days). Stohs et al.
concluded that banaba extract and corosolic acid could improve
symptoms associated with metabolic syndrome as well as offer-
ing other health benefits. In fact, patients treated with pure coro-
solic acid (10mg/30 days) had decreased blood sugar levels with-
in 60min. The authors also hypothesize that beneficial effects of
banaba and corosolic acid with respect to glucose metabolism
appear to involve multiple mechanisms, including enhanced cel-
lular uptake of glucose, impaired hydrolysis of sucrose and
starches, and decreased gluconeogenesis. These effects could be
mediated by PPAR, MAPK, and NF-κB [112].
Bitter melon
M. charantia is a climbing perennial plant that produces elon-
gated fruits with a pronounced bitter taste, which is known as
bitter melon or bitter gourd [113]. This species has been studied
in vitro and in vivo for its potential antidiabetic properties, with
different parts of this plant (seeds, fruit pulp, leaves, and whole
plant) and different doses (from 400mg to 6 g/day) being as-
sayed. In experiments using rats, M. charantia improves glucose
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d.tolerance, suppresses postprandial hyperglycemia, and enhances
insulin sensitivity. Several mechanisms of action have been pro-
posed such as induction of glucose uptake and increased adipo-
nectin secretion [41], activation of the AMPK system, and PPARα
and PPARγ receptor activation. PPARα and PPARγ are pivotal in
lipid and glucose hemostasis and may mitigate insulin resistance
[106]. Different compounds have been isolated and some of them
have been implicated as potential active principles such as α-
eleostearic acid (9-cis, 11-trans, 13-trans octadecatrienoic acid)
as a PPARα activator [114]. However, a Zn-free protein bearing in-
sulinomimetic activities has been isolated from the fruit of this
plant [115], which could be related to the protein called “vegeta-
ble insulin” reported 30 years ago [113].
Nahas and Moher [37] reviewed previous clinical trials and cited
one with 40 and a second with 51 patients in which no effects on
HbA1c or fasting blood glucose were reported. Leung et al. [113]
compiled ten clinical studies performed until 2008, but only five
were relevant and only four were designed as clinical trials. Some
of these reported significant results in the reduction of both fast-
ing and postprandial sugar levels. However, the different size of
the trials, forms of administration (methanol extract, dried pow-
der, fresh fruit or enriched fraction), dosage (timing and dose),
and outcome measures (HbA1c, postprandial sugar levels or oral
glucose tolerance test), use of the same subjects as controls and
trials, different reports on adverse effects, etc., render these stud-
ies only relatively interesting for the use of this medicinal plant as
an antidiabetic.
Ooi et al. [116,117] compiled randomized, controlled trials that
compared M. charantia for T2DM with a placebo or a control in-
tervention, with or without pharmacological or non-pharmaco-
logical interventions. Four randomized, controlled trials with up
to three monthsʼ duration and studying 479 participants met the
inclusion criteria. The results showed no statistically significant
difference in glycemic control with M. charantia preparations
compared to the placebo or reference drugs metformin and gli-
benclamide. No serious adverse effects were reported in any trial.
Medagama and Bandara [118] reviewed the clinical trial of bitter
melon and cited several objections to establishing its clinical effi-
cacy: heterogeneity of patients, doses (0.5 to 6 g/day), method of
preparation, dosage, and primary outcome measures in the dif-
ferent studies. A relevant point was that two studies used dried
fruit and another used a commercially available preparation.
However, when fresh juice was used in a case series, there was a
significant reduction of fasting plasma glucose and postprandial
plasma glucose. These effects could indicate the importance of
the type of fruit and method of preparation for future studies.
Caper
Caper bush, Capparis spinosa L. (Capparaceae), is a perennial
plant with edible flower buds (capers) and fruit (caper berries).
The fruits are traditionally used as antihyperglycemic food by Ira-
nian diabetic patients. Huseini et al. [119] conducted a random-
ized clinical trial with 54 patients (40–65 years of age) with es-
tablished T2DM and standard antidiabetic therapy. For 2 months
the treated group (n = 28) received 400mg extract × 3 each day
vs. placebo (n = 26). The results showed a significant decrease in
fasting blood glucose levels (11.2%) and HbA1c (4.8%) in caper-
treated patients compared to the control, whereas the placebo
group also had a clear reduction when compared with controls,
4.2% and 2.0%, respectively, in fasting blood glucose levels and
glycosylated hemoglobin at the end of the study. However, other
parameters showed a higher reduction, such as triglyceride level(24%) in the caper-treated group vs. control (16%). The authors
concluded that caper fruits could be used as an adjuvant agent
for the treatment of diabetic patients. However, these authors
specify some deficiencies of their study, such as the small sample
size and lack of identification of active constituents.
Cinnamon
Cinnamon, Cinnamomum cassia Siebold (Lauraceae), is a spice
with high global consumption. It was claimed to be a natural in-
sulin sensitizer in adipocytes and in different animal models
[120–124]. In these studies, different active compounds were iso-
lated and identified, such as a methylhydroxychalcone polymer
with insulin-mimetic effects [123,124], but the study was not
confirmed by Anderson et al. [125] who suggested that the active
compounds had been likely misidentified.
In 2003, Khan et al. [126] published the first study on cinnamon
supplementation in humans, which reported a clear reduction in
fasting glycemia (18–29%) after 40 days of daily supplementation
with only 1, 3, or 6 g of cinnamon in patients with T2DM. Howev-
er, this study did not report any dietary standardization during
the intervention, and the authors did not include potential
changes in blood insulin and/or HbA1c concentrations. More re-
cently, Vanschoonbeek et al. [127] designed a similar study but
with 25 postmenopausal patients with T2DM that were supple-
mented with either cinnamon (1.5 g/day) or a placebo, conclud-
ing that cinnamon supplementation does not improve whole-
body insulin sensitivity or oral glucose tolerance in these pa-
tients.
Pham et al. [128] reviewed clinical trials and found two prospec-
tive, randomized, double-blind, placebo-controlled, peer-re-
viewed clinical trials and one prospective, placebo-controlled,
peer-reviewed clinical trial that evaluated the efficacy of cinna-
mon supplementation (1 to 6 g/day) in patients with T2DM, with
a total of 164 patients involved in these trials. Two of these trials
reported modest improvements of glycemia, suggesting that cin-
namon has a quite modest effect on glycemia in patients with
poorly controlled T2DM.
Kirkham et al. [129] reviewed the therapeutic potential of C. ve-
rum and C. cassia in patients with diabetes and insulin resistance,
particularly their ability to reduce blood glucose levels and inhib-
it protein glycation. Two of the studies showed significant fasting
blood glucose reductions (between 10 and 29%), one of them re-
ported an 8.4% reduction vs. the placebo, and another reported a
significant reduction in glucose response using oral glucose toler-
ance tests. Doses varied from 1 to 10 g/daily, and 1 to 3 months.
Three diabetic studies selected reported no significant results.
Two years later, Davis and Yokoyama [130] made a meta-analysis
of clinical studies, including three new clinical trials along with
five trials used in previous meta-analyses, using a literature
search of randomized, placebo-controlled trials reporting data
on cinnamon and/or cinnamon extract effects on fasting blood
glucose in T2DM or prediabetic patients. They reported that the
intake of cinnamon or its extract results in a significant lowering
in fasting glycemia of about − 0.5mmol/L in these patients [124].
In 2012, Leach and Kumar [131] reviewed randomized, con-
trolled trials comparing the effects of orally administered cinna-
mon (2 g/day for a period ranging from 4 to 16 weeks) vs. a
placebo, active medication, or no treatment. After identifying
ten prospective, parallel-group designs, randomized controlled
trials, involving 577 participants, the authors concluded that the
effect of cinnamon on fasting blood glucose level is not conclu-
sive. However, the same year, Akilen et al. [132] reported a sys-Ríos JL et al. Natural Products for… Planta Med 2015; 81: 975–994
Fig. 10 Chemical
structures of flavan-3-
ols, 4-hydroxyisoleu-
cine, and trigonelline.
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d.tematic review and meta-analysis on the effect of cinnamon on
glycemic control in patients with T2DM (six clinical trials with a
total of 435 patients, 40 days to 4 months, 1 to 6 g per day). The
results showed a significant decrease in mean HbA1c and fasting
plasma glucose, concluding that the use of cinnamon could be
beneficial for glycemic control and that the short-term (< 4
months) effects of its use look promising.
In conclusion, although cinnamon clearly possesses antihyper-
glycemic properties and the potential to reduce postprandial
blood glucose levels, no definitive conclusions can be established
for its use in antidiabetic therapy.
Cocoa
Cocoa, Theobroma cacao L. (Sterculiaceae), and its derivatives are
of interest in the prevention of cardiovascular disease [133,134].
In a clinical trial, Grassi et al. [135] studied the effect of flavanols
from chocolate on different cardiovascular risk factors in hyper-
tensive patients, including insulin sensitivity and β cell function.
They used two groups of hypertensive patients, randomized to
receive either flavanol-rich dark chocolate or flavanol-free white
chocolate (100 g/day for 15 days). The results showed that the
first group but not the second decreased insulin resistance and
increased insulin sensitivity and β cell function. Some years later,
Hooper et al. [136] realized a systematic review on the effects of
cocoa, chocolate, and flavan-3-ols (l" Fig. 10) on the classic risk
factors, and also considered the reciprocal relation between insu-
lin resistance and endothelial dysfunction [137] as well as other
independent predictors such as fasting glucose, insulin, and
HbA1c. The review, including 42 acute or short-term, random-
ized controlled trials with 1297 patients, showed that chocolate
or cocoa induced a significant reduction in serum insulin without
negative effects, thus suggesting insulin resistance improvement
[136].
Coffee
Seeds of coffee, Coffea arabica L. (Rubiaceae), intake is associated
with a reduced risk of T2DM. To confirm this property, Salazar-
Martínez et al. [138] examined the long-term relationship be-
tween the consumption of coffee and other caffeinated beverages
and the incidence of T2DM in a prospective cohort study (The
Nursesʼ Health Study and Health Professionalsʼ Follow-up Study).
They followed up 41934 men (1986 to 1998) and 84276 women
(1980 to 1998) without diabetes, and 1333 new cases of T2DM in
men and 4085 new cases in women were documented. They
found an inverse association between coffee intake and T2DM,
thus suggesting that long-term coffee consumption is associated
with a significantly lower risk for the disease [138]. This effect
was associated with mineral and antioxidant contents, but the
role of caffeine was not specified until the Pereira et al. study
[139]. These authors demonstrated in a prospective analysis with
a cohort of 28812 postmenopausal women free of diabetes of the
Iowa Womenʼs Health Study (1986–1997) that coffee intake, es-
pecially decaffeinated, was inversely associated with a risk of
T2DM.
Fenugreek
Seeds of fenugreek (T. foenum-graecum) are used to enhance fla-
vor, color, and texture of food, and are also used for medicinal
purposes. Different epidemiological and laboratory studies have
ratified their medicinal properties [140–143]. Studies in humans
demonstrated that fenugreek exerts hypoglycemic effects by
stimulating glucose-dependent insulin secretion from pancreaticRíos JL et al. Natural Products for… Planta Med 2015; 81: 975–994β cells and increasing the number of insulin receptors as well as
by inhibiting the activity of α-amylase and sucrase [140]. Pre-
vious clinical trials were run with weak methodology and lacked
an adequate description of blinding, randomization, baseline pa-
tientsʼ characteristics, statistical analysis, and standardization
data for the therapy used [140].
Recently, Neelakantan et al. [144] reviewed clinical trials on the
effect of fenugreek intake on markers of glucose homeostasis.
Ten trials were identified in which fenugreek significantly
changed fasting blood glucose, post-load glucose, and HbA1c
compared to control interventions. Heterogeneity of results was
partly justified by the diabetes status of the patients, study de-
sign (parallel or crossover), study duration (< 30 days or ≥ 30
days), and dose employed (< 5 g, 5–10 g, or > 10 g) since signifi-
cant effects on fasting and 2 h glucose were found only in studies
performed in diabetic patients that received medium or high
doses of fenugreek. In conclusion, clinical trials support beneficial
effects of fenugreek seeds on glycemic control in persons with
diabetes.
Several studies identified different compounds responsible for
the abovementioned effects. Basch et al. [140] established that
the amino acid 4-hydroxyisoleucine (l" Fig. 10) is responsible for
the increase in glucose-induced insulin release in humans, acting
on pancreatic β cells. Another potential active principle is tri-
gonelline (l" Fig. 10), the major alkaloid component of fenugreek,
which has hypoglycemic activity, reduces diabetic auditory neu-
ropathy, and affects β cell regeneration, insulin secretion, and ac-
tivities of enzymes related to glucose metabolism as well as anti-
oxidant capacity [145]. Swaroop et al. [143] cited the furostanolic
Fig. 11 Chemical structures of gymnemic acids and gurmarin.
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d.saponins as active compounds, whereas Perla and Jayanty [24]
established that biguanide-related compounds could be, in part,
the active principles given that fenugreek seeds contain a rele-
vant amount of these compounds (18.98 µg/g).
Garlic
Garlic, Allium sativum L. (Alliaceae), has been used in India for its
antidiabetic properties since ancient times [49]. In recent years,
different in vitro and in vivo studies demonstrated garlicʼs antihy-
perglycemic effects. Ackermann et al. [146] reviewed the effects
of garlic on several cardiovascular-related factors and its adverse
effects; after analyzing 45 randomized trials, they observed no ef-
fects on glycemic-related outcomes. In their conclusions, the au-
thors recommend future studies with clear definitions of constit-
uents and preparations, because in these clinical trials there are
great variations of samples (oil macerate, aged garlic, and differ-
ent kinds of extracts) and doses (from 10mg to 10 g). Some years
later, Mohammadi and Oshaghi [147], working with mice, ob-
served that garlic extract antagonized LXRα, an important regu-
lator of cholesterol, triglycerides, and glucose homeostasis, and
increased LXRα expression in the intestine. These effects could
have an important role in the reduction of the lipid profile by gar-
lic, which would justify the potential for this treatment of diabe-
tes, but it should be demonstrated in humans.
Guava
Psidium guajava L. (Myrtaceae) or guava, also known as guayaba
(Spanish), is a food crop and medicinal plant from tropical coun-
tries whose leaves (water extract) are used to reduce hyperglyce-
mia in diabetic patients in Mexico. Many papers describing its
pharmacological activities have been published, and Gutiérrez
et al. reported two clinical assays [148]. In one paper in China, a
multicentric, randomized, controlled trial evaluated the efficacy
of guava in diabetes management. After oral administration of
500mg of aqueous leaf extract to 50 diabetic patients, they con-
sidered that guava could be used as a complementary therapy for
preventing and treating diabetes mellitus, but not as a principal
agent, since it is less effective than standard drugs. In the second
trial, oral administration of 500mg (fruit) to 40 patients de-
creased glycemia after 3 weeks of treatment compared to the di-
abetic control group.
Gymnema
The leaf of G. sylvestre is a reputed herb in both Ayurvedic and
Western medicines. It shows positive effects on blood sugar ho-
meostasis and controls sugar cravings [149]. It acts through the
stimulation of insulin secretion from pancreatic β cells, and some
active compounds have been cited such as gymnemic acids and
gurmarin, a 35-amino-acid peptide (4209 MW) (l" Fig. 11). Ko-
saraju et al. [88] demonstrated that Gymnema showed a limited
effect on GLP-1 levels, although other effects, such as the interac-
tion with glyceraldehyde-3-phosphate dehydrogenase, a key en-
zyme in glycolysis pathway, have been described [149]. Comple-
mentary mechanisms were described for this species, such as the
modulation of the enzymes responsible for glucose utilization
(increased phosphorylase activity and decreased activity of glu-
coneogenic enzymes and sorbitol dehydrogenase) and inhibition
of glucose absorption in the bowel [150]. Other effects of Gymne-
ma extract include a prolonged hypoglycemic action of exoge-
nous insulin in dogs without a pancreas, intensification of effects
of insulin, and extended duration of reduced glucose levels. These
effects were observed after administration of the extract, thesaponin fraction, or isolated triterpene glycosides [150,151].
Some of these properties have been confirmed in different clini-
cal trials conducted in the US with a patented preparation based
on a standardized extract (400mg/day), but 27 patients with
type 1 diabetes mellitus with insulin therapy were studied, and
it was concluded that Gymnema increases the endogenous levels
of insulin, possibly due to pancreatic regeneration [150]. Howev-
er, two small, open-label trials have also yielded promising re-
sults after administration of Gymnema to patients with T2DM. In
the first trial, patients that received 200mg daily for 18 to 20
months of an ethanolic extract significantly improved fasting
blood glucose and HbA1c levels. The second trial was uncon-
trolled, and patients that received 800mg daily of a similar ex-
tract for 3 months reduced fasting blood glucose and HbA1c lev-
els; however, they used a mixed population of 65 patients with
type 1 and type 2 diabetes. In conclusion, Gymnema reduced
HbA1c levels and appears to improve glycemic control, although
complementary studies are necessary [37]. In a later study, T2DM
patients received 500mg herb/day for 3 months and the treated
group reduced both fasting and postprandial blood glucose and
HbA1c [152]. All together, these findings suggest that Gymnema
extract could be beneficial for the management of diabetes melli-
tus.
Nettle
U. dioica is a herbaceous perennial flowering plant with many
hollow stinging hairs on the leaves and stems, which break off to
leave a sharp, needle-like tube that pierces the skin and injects
histamine and acetylcholine, causing itching and burning. Its
roots are used against benign prostatic hyperplasia and its leaves
are used in traditional medicine as an antihyperglycemic agent to
treat diabetes mellitus [153]. Studies in animals demonstrated
that nettle leaves have insulin secretagogue, PPARγ agonistic,
and α-glucosidase inhibitory effects [69,154]. Kianbakht et al.
[155] ran a randomized, double-blind, placebo-controlled clinical
trial to evaluate the effects of nettle leaf extract (500mg/8 h, 3
months) combined with conventional oral antihyperglycemic
drugs. The clinical trial included 46 treated patients vs. 46 in the
placebo group. At the endpoint, the extract significantly loweredRíos JL et al. Natural Products for… Planta Med 2015; 81: 975–994
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d.the blood levels of fasting glucose, 2 h postprandial glucose, and
HbA1c, without significant effects on other hepatic or cardiovas-
cular parameters vs. the placebo. All considered, these results
demonstrated that nettle is safe and may have a beneficial effect
on glycemic control in patients with advanced T2DM needing in-
sulin therapy. Nettle may also improve efficacy of conventional
oral antihyperglycemic drugs to control glycemia, although the
authors consider that further trials with a larger number of pa-
tients to assess the efficacy and safety of nettle as well as more
studies addressing mechanisms and bioactivity involved in its
antidiabetic effects are necessary [155].
Sage
Leaves of S. officinalis are used to treat digestive and metabolic
disorders including T2DM [156]. Their antihyperglycemic effect
has been studied in different animal model of diabetes [157,
158] and in a crossover trial with six healthy female volunteers
[159] as well as a 2-month randomized, double-blind, placebo
controlled trial [160], but no glycemia was assayed. However,
two years later, the last authors evaluated the efficacy and safety
of a sage leaf extract in the treatment of 86 hyperlipidemic T2DM
patients using a randomized, placebo-controlled, parallel group
study with 42 treated patients treated with leaf hydroethanolic
extract (500mg/8 h for 3 months) and 44 as placebo groups. In
this case, fasting glucose and HbA1c values were determined, to-
gether with the lipidemic profile. They described that the leaf ex-
tract lowered fasting glucose and HbA1c compared to the base-
line at the endpoint with no adverse effects reported. Therefore,
they concluded that sage leaves might be safe and have antihy-
perglycemic effects in hyperlipidemic T2DM patients since the
lipidemic profile also improved [156].
Soybean
Estrogens have been reported to be beneficial for the prevention
and treatment of T2DM by attenuating insulin resistance, im-
proving insulin secretion, and increasing the β cell mass [161].
As a result, there are some studies on the potential of isoflavo-
noids derived from Glycine max (L.) Merr. (Fabaceae) as antidia-
betic agents since they may improve glucose homeostasis
through estrogenic action. Other authors also reported that,
although the lack of testing with human subjects does not permit
definitive conclusions, evidence suggests that fermented soy
products may be better for preventing or delaying the progres-
sion of T2DM compared to nonfermented soybeans [162].
Some years later, Zhang et al. [163] conducted a systematic re-
view and meta-analysis to confirm the effects of soy isoflavone
supplementation on body weight and fasting glucose and insulin
levels in non-Asian postmenopausal women. They analyzed
three groups: a) nine studies with 528 participants for body
weight, b) eleven studies with 1182 participants for fasting glu-
cose, and c) eleven studies with 1142 participants for fasting in-
sulin. The dose of treatment varied from 40 to 160mg, and the
duration varied from 8weeks to 1 year. They observed significant
reductions in body weight and glucose and fasting insulin levels
with soy isoflavone supplementation compared to the placebo
control group. Isoflavones could also significantly reduce blood
glucose in longer treatments (> 6 months) in postmenopausal
women. The authors concluded that soy isoflavones could be
beneficial for glucose and insulin control as well as body weight
reduction, but they recommended larger and well-designed
studies to confirm these data.Ríos JL et al. Natural Products for… Planta Med 2015; 81: 975–994Tea
Various studies report that polyphenolic compounds present in
green and black tea (C. sinensis) are associated with beneficial ef-
fects in the prevention of cardiovascular disease and antidiabetic
properties [164]. In this direction, different studies have been de-
signed in order to identify the effects of tea on glucose metabo-
lism and insulin signaling as well as possible positive effects on
patients with established diabetes. The Womenʼs Health Study
described that tea drinkers (drinking ≥ 4 cups of tea/day) had a
30% lower risk for developing T2DM vs. non-tea consuming
women [165]. In the Japanese, who consume ≥ 4 cups of green
tea daily, there is a 33% reduced risk for diabetes, but no reduc-
tionwas observed for red or black teas [166]. However, Neyestani
et al. [167] reported the positive effect of black tea intake on dif-
ferent biomarkers in the serum of patients with T2DM (total anti-
oxidant capacity, MDA, C-reactive protein, and GSH levels). The
positive effect of green teawas correlatedwith the continuous in-
gestion of catechin-rich beverages. In effect, in a double-blind,
controlled study, patients with T2DMwithout insulin therapy re-
ceived green tea (582.8mg catechins or 96.3mg of catechins/day
for 12 weeks) and at the end of the trial, there was an increase in
insulin and a decrease in HbA1c levels in the catechin group vs.
the control [168].
Turmeric
The dried powder of the rhizome of Curcuma longa L. (Zingibera-
ceae) has been used for centuries as a medicinal agent and specif-
ically as an antidiabetic drug. Both the rhizome extract and its
principal component, curcumin (l" Fig. 8), have been extensively
studied. However, studies over the past decade have indicated
that curcumin-free turmeric components also possess antidia-
betic properties [169]. Gupta et al. [170] compiled data from clin-
ical trials on turmeric, including diabetes. One study examined
the effects of turmeric on postprandial plasma glucose and insu-
lin levels and the glycemic index in 14 healthy subjects in a cross-
over trial. Ingestion of turmeric increased postprandial serum in-
sulin levels without affecting glycemia or the glycemic index,
thereby suggesting an effect on insulin secretion [171]. In a com-
plementary study, Khajehdehi et al. [172] investigated the effects
of turmeric on serum and urinary TGF-β, IL-8, and TNF-α as well
as proteinuria on 40 patients with overt T2DM nephropathy.
They were randomly assigned to either a trial group (500mg of
turmeric, 3 times/day, 2months) or the control group. The results
showed that serum concentrations of the parameters studied
(TGF-β, IL-8, and TNF-α) decreased significantly with no adverse
effects related to turmeric supplementation. Because TGF-β plays
a key role in the pathogenesis of diabetic nephropathy, and ele-
vated concentrations of serum TNF-α and urinary levels of IL-8
are associated with a decline in renal function in type 1 diabetic
nephropathy, turmeric supplementation in a diet could be a
promising approach as a safe and effective alternative therapy
for T2DM nephropathy [172].
Other studies on diabetic retinopathy established that the thera-
peutic potential of curcumin for delaying this damage is exerted
through its antioxidant and anti-inflammatory properties as well
as inhibition of vascular endothelial growth factor, stromal cell-
derived factor 1, and PPARγ [173]. However, since the digestive
system poorly absorbs dietary curcumin, this fraction becomes
inactive by glucuronidation and is instead excreted. In conse-
quence, it is unclear how dietary curcumin exerts its beneficial ef-
fects in T2DM and associated diseases. Therefore, Maradana et al.
[174] reviewed new methods of delivering curcumin, including
989Reviews
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.nanoparticles and lipid/liposome formulations that increase in-
testinal absorption and bioavailability of curcumin. For example,
a curcumin-phosphatidylcholine complex (Meriva, 1 g/day, 4
weeks) increases bioavailability of oral curcumin and is safe for
human use. These preliminary findings suggested the usefulness
of this and other curcumin formulations for the management of
diabetic microangiopathy, although further studies are necessary
to determinate whether curcumin/lipid complexes increase the
efficacy of oral curcumin alone.
Walnut
J. regia is known as the commonwalnut tree and its fruits as wal-
nuts. The leaves of this tree are traditionally used for the treat-
ment of diabetes in different Asiatic andMediterranean countries
[175]. Different in vitro and in vivo studies in animals determined
its potential value as an antidiabetic medicinal plant [176–181].
In order to determine the effects on humans, Hosseini et al.
[176,179] studied the effects of an aqueous leaf extract on 58 Ira-
nian T2DM patients. Male and female patients were randomly di-
vided into two groups. One group (n = 30) received 100mg of leaf
extract twice per day for 3 months, and the other a placebo
(n = 28). HbA1c, blood glucose, insulin, serum glutamic oxaloace-
tic transaminase, serum glutamate-pyruvate transaminase, and
alkaline phosphate levels were evaluated at the beginning and
after 2 months of the trial. Serum fasting HbA1c and blood glu-
cose levels significantly decreased, and the insulin level increased
in the group treated with walnut leaf extract. In a complementa-
ry study, the same authors studied 61 T2DM patients (40–60
years of age) with a fasting blood glucose between 150 and
200mg/dL and HbA1c between 7 and 9%, and randomly divided
them into two groups. The treatment group received 100mg of
leaf extract, twice per day for 3 months. The standard antidia-
betic therapy (metformin and glibenclamide) as well as nutri-
tional diet were followed in both groups. After three months,
the glucose and HbA1c levels of the treated patients had signifi-
cantly decreased compared to the placebo group, and no relevant
side effects were observed [175,179]. In vitro studies proposed
that the inhibition of α-amylase [69], the inhibition of glycation
and oxidation reactions [180], and the inhibition of PTP1B [93]
were possible mechanisms of action.
Yerba mate
Ilex paraguariensis A.St.‑Hil. (Aquifoliaceae), commonly known
as “yerba mate” or “té del Paraguay”, was originally used to pre-
pare psychostimulant beverages, but was subsequently included
in phytotherapy worldwide [181–183]. In addition to its effects
on the nervous system, other effects such as vasodilator, hypoli-
pidemic associated with weight reduction, and antidiabetic,
mainly by virtue of its antioxidant capacity, have been described.
Some in vivo studies have also been done in recent years. Oliveira
et al. [184] evaluated the antidiabetic properties of yerba mate
extract in alloxan-induced diabetic Wistar rats and demonstrat-
ed that yerba mate interfered with glucose absorption in the gut
by decreasing SGLT1 expression. However, no significant differ-
ences in serum glucose, insulin, and hepatic glucose-6-phospha-
tase activity vs. the control were observed. Yerba mate extract al-
so affects food intake, lipid metabolism, and glucose concentra-
tions [185], and ameliorates insulin resistance in mice with
high-fat diet-induced obesity [186]. In this last study, the authors
demonstrated a restoration of hepatic, IRS-1, and protein kinase
B (Akt) phosphorylation. In addition, the high-fat diet caused the
upregulation of TNF-α, IL-6, and iNOS gene expression and a re-duction of NF-κB nuclear translocation. It is known that the TNF-
α receptor results in the serine phosphorylation of IRS-1, which
attenuates its ability to transduce insulin-mediated cellular
events [186]. In a complementary study, Pereira et al. [187] dem-
onstrated that the polar fractions (polyphenols) from yerba mate
induced insulin secretion, inhibited in vitro disaccharidase activ-
ities with a maximum inhibitory effect on maltase activity of
35%, and reduced protein glycation by glucose or fructose by
around 50% and 90%, respectively. They concluded that yerba
mate has a potential antihyperglycemic role that may be able to
improve diabetic status and could be a source of multiple hypo-
glycemic compounds.
As mentioned in the introduction, obesity is associated with an
increased risk of developing insulin resistance and T2DM. It is
well known that adipose tissue of obese individuals releases in-
creased amounts of non-esterified fatty acids, glycerol, hor-
mones, and pro-inflammatory cytokines (adipokines) involved
in the development of insulin resistance and T2DM [188]. De
Morais et al. [189] showed that yerba mate intake by dyslipidem-
ic individuals had antiobesity activity (330mL of green or roasted
yerba mate infusions, 3 times per day for 40 days). A 60-day in-
tervention pilot study evaluated the effects of roasted mate tea
consumption (330mL, 3 times per day), with or without dietary
counseling, on glycemic and lipid profiles of individuals with
T2DM or prediabetes [190]. Mate tea consumption significantly
decreased the levels of fasting glucose, glycated HbA1c, and LDL‑c
in T2DM subjects, and in prediabetic individuals, LDL‑c, non-
HDL‑c, and triglycerides diminished significantly. More recently,
in another pilot study, the effects of yerba mate were also studied
in 11 T2DM and 11 prediabetic volunteers (1 L/day of mate tea)
[191]. T2DM subjects showed a significant reduction in fasting
plasma glucose and HbA1c after 60 days of mate tea consump-
tion; however, normal values were not achieved. In prediabetic
individuals, mate tea intake did not promote a decrease in fasting
plasma glucose, but did significantly lower the HbA1c concentra-
tion after 40 days of treatment.Future Perspectives and Conclusions
!
Varied and interesting approaches have been proposed for treat-
ing T2DM. There are many preclinical studies in animals as well
as screening of medicinal plants used for treating diabetes in dif-
ferent parts of the world. However, the major interest could be
the increasing number of systematic reviews on clinical trials de-
veloped in recent times. They open new possibilities with a high
level of credibility in the field of medicinal plants and natural
products. Some new aspects in research are introduced and some
points of view could be of high interest, such as genomic, metab-
olomics, or in silico studies. For example, Anuradha [192] re-
viewed the nutrigenomic approaches based on ethnopharmacol-
ogy and phytotherapy concepts and their relation to T2DM. In-
deed, the interaction between bioactive food components and
the genomemay influence cell processes and modulate the onset
and progression of T2DM, the disease being susceptible to dietary
intervention. The authors identified many phytochemicals from
traditional medicinal plants that can target diabetogenic genes,
and established a future application of nutritional therapy for
the modification of genes relevant for diabetes. Other authors
propose the use of a structure-based design of compounds from
natural sources for diabetes. From the literature, they selected
three targets: α-glucosidase, aldose reductase and PTP1B en-Ríos JL et al. Natural Products for… Planta Med 2015; 81: 975–994
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d.zymes, and carried out a high throughput virtual screening fol-
lowed by induced fit docking studies. They applied this study to
a number of natural products, and concluded that some of the
natural inhibitors successively satisfied all the in silico parame-
ters and could be of interest as antidiabetic agents [193].
In the near future, some interesting new sources should be tested
and their active principles studied. For example, Melzig and
Funke [68] proposed blueberry (leaves), tamarind, lemon balm,
rosemary, white kidney beans (hulls) and green tea as medicinal
plants with high interest for clinical trials. Other aspect to be con-
sidered for future research is the potential effect on specific or
new targets implicated in T2DM. As a proof of concept the study
of the bark of apple trees as SGLT2 inhibitor drove to the isolation
of phlorizin, and then several semisynthetic derivatives were ob-
tained and used as antidiabetic drugs, such as sergliflozin, remo-
gliflozin, canagliflozin and dapagliflozin [84,85].
Other aspect of interest is the potential interaction and posibles
incompatibilities of antidiabetic plants with drugs used in human
medicine as was described by the European Medicines Agency
(EMA) and The European Scientific Cooperative on Phytotherapy
(ESCOP), and reviewed and summarized by Vanaclocha et al.
[194]. Some of them are the negative effect on digestive absorp-
tion of drugs in presence of fenugreek due to its mucilages, or the
case of plants with caffeine, such as mate and green tea, that can
interfere with sedative and adrenergic drugs. Other described in-
teractions are garlic with anticoagulants, as well as many plants
with hypogliycemic medications, such as gymnema or fenugreek
[195,196]. There are also potential interaction between medici-
nal plants with dual effects and medicines. For example, olive
leaves have antidiabetic and antihypertensive effects, and people
that use extracts from that as antidiabetic some time can have
hypotensive crisis and vice versa [197].
In conclusion, natural products, especially those of plant origin,
are important sources of compounds with different chemical
structures which, acting through diverse mechanisms, could of-
fer a therapeutic alternative to treat T2DM. Since results with
several of these compounds are preliminary or inadequately
documented, it is necessary to continue working on their re-
search and development before using them as new antidiabetic
drugs.Th
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